Quantcast

Latest Ataxia Stories

2009-09-26 08:58:00

Discovery takes researchers 1 step closer to human clinical trials and could improve understanding of other diseases Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials,...

2009-09-25 11:15:00

WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. The study entitled "Chemical Probes...

2009-07-22 09:00:00

WALNUT CREEK, Calif., July 22 /PRNewswire/ -- Fragile X Syndrome (FXS) research is moving closer to finding a cure with the recent approval by The National Institutes of Health (NIH) of a comprehensive plan created by a group of leading scientists, parents and advocates. The Congressional Fragile X Caucus is convening a Congressional briefing to highlight the work of the NIH's Research Plan on Fragile X Syndrome and Associated Disorders and to celebrate National Fragile X Awareness Day in...

2008-12-22 15:22:00

ST. PETERSBURG, Fla., Dec. 22 /PRNewswire/ -- On December 17th, the new Bonefish Grill restaurant located at 5062 4th Street North in St. Petersburg, opened its doors to friends and supporters of Friedreich's Ataxia Research Alliance for Heineken with a Heart, a social event sponsored by Bonefish Grill, SafeCall and Heineken USA to benefit local charities. (Logo: http://www.newscom.com/cgi-bin/prnh/20080212/CLTU083LOGO ) Guests took part in complimentary Bonefish Grill delights...

2008-10-10 09:00:18

LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada. The drug is indicated for the treatment of Friedreich's Ataxia, a rare neuromuscular disease that results in the degeneration of nerve and muscle tissue. Catena is the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera...

2008-09-29 21:00:31

NEW HAVEN, Conn., Sept. 29, 2008 (GLOBE NEWSWIRE) -- People who suffer from health disorders are often treated as outcasts by society, often feared and even discriminated against. As such, the need to educate the public and help them understand the plight of sufferers simply cannot be ignored. And most of all, people must understand that sufferers still have the chance to live normally and be free from unneeded negative perception. These are some of the lessons that readers are about to...

2008-07-24 12:01:22

Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena. Launch of Catena is anticipated by the end of October 2008. In clinical studies submitted to Health Canada as part of the approval process,...

2008-07-24 03:00:18

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena(R). Santhera has established a wholly owned Canadian subsidiary,...

2004-11-26 03:00:10

Cerebellar atrophy has been recognized as an occasional feature of systemic lupus erythematosus (SLE)1,2 but not systemic sclerosis. CASE HISTORY The patient was a woman whose illness had begun at the age of 40 with Raynaud's phenomenon, progressing to distal necrosis and ulceration of fingertips, with sclerosis of the hands, feet and face. The results of investigation were consistent with systemic sclerosis (SS). Subsequently she reported heartburn and regurgitation, and oesophageal...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related